VERICEL CORPORATION Amortization of Intangible Assets
VERICEL CORPORATION (VCEL) reported Amortization of Intangible Assets of $300.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2017-03-13
- VERICEL CORPORATION amortization of intangible assets for the quarter ending 2016-12-31 was $100.00K, a 0.00% change year-over-year.
- VERICEL CORPORATION amortization of intangible assets for the quarter ending 2016-09-30 was $100.00K, a 0.00% change year-over-year.
- VERICEL CORPORATION amortization of intangible assets for the quarter ending 2016-06-30 was $100.00K, a 0.00% change year-over-year.
- VERICEL CORPORATION amortization of intangible assets for the quarter ending 2016-03-31 was $100.00K, a 0.00% change year-over-year.
- VERICEL CORPORATION amortization of intangible assets for fiscal 2016 was $300.00K, a 0.00% change from fiscal 2015.
- VERICEL CORPORATION amortization of intangible assets for fiscal 2015 was $300.00K, a 50.00% increase from fiscal 2014.
- VERICEL CORPORATION amortization of intangible assets for fiscal 2014 was $200.00K.
- VERICEL CORPORATION amortization of intangible assets for fiscal 2013 was $0.00.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2016-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $200.00K derived: sum of 2 quarters · filed 2017-03-13 | $300.00K derived: sum of 3 quarters · filed 2017-03-13 | $300.00K 10-K · filed 2017-03-13 |
| 2016-09-30 | $100.00K 10-Q · filed 2016-11-07 | $200.00K derived: sum of 2 quarters · filed 2016-11-07 | $200.00K 10-Q · filed 2016-11-07 | $400.00K derived: sum of 4 quarters · filed 2017-03-13 |
| 2016-06-30 | $100.00K 10-Q · filed 2016-08-08 | $200.00K 10-Q · filed 2016-08-08 | $300.00K derived: sum of 3 quarters · filed 2017-03-13 | $400.00K derived: sum of 4 quarters · filed 2017-03-13 |
| 2016-03-31 | $100.00K 10-Q · filed 2016-05-10 | $200.00K derived: sum of 2 quarters · filed 2017-03-13 | $300.00K derived: sum of 3 quarters · filed 2017-03-13 | $400.00K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $200.00K derived: sum of 2 quarters · filed 2017-03-13 | $300.00K derived: sum of 3 quarters · filed 2017-03-13 | $300.00K 10-K · filed 2017-03-13 |
| 2015-09-30 | $100.00K 10-Q · filed 2015-11-13 | $200.00K derived: sum of 2 quarters · filed 2015-11-13 | $200.00K 10-Q · filed 2015-11-13 | $400.00K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-06-30 | $100.00K 10-Q · filed 2015-08-12 | $200.00K 10-Q · filed 2015-08-12 | $300.00K derived: sum of 3 quarters · filed 2017-03-13 | $370.00K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-03-31 | $100.00K 10-Q · filed 2015-05-14 | $200.00K derived: sum of 2 quarters · filed 2017-03-13 | $270.00K derived: sum of 3 quarters · filed 2017-03-13 | $290.00K derived: sum of 4 quarters · filed 2017-03-13 |
| 2014-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $170.00K derived: sum of 2 quarters · filed 2017-03-13 | $190.00K derived: sum of 3 quarters · filed 2017-03-13 | $200.00K 10-K · filed 2017-03-13 |
| 2014-09-30 | $70.00K 10-Q · filed 2014-11-13 | $90.00K derived: sum of 2 quarters · filed 2014-11-13 | $100.00K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $20.00K 10-Q · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |